Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemo-Immunotherapy for Stage I-IIIB NSCLC
NCT04941417Phase 2Unknown
- Sponsor
- Peking Union Medical College
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College. Primary endpoint: Major Pathologic Response at 8 weeks. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04941417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941417.